• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

    5.920 -0.250 (-4.05%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,577,892
    Open 6.160
    Bid (Size) 5.950 (13)
    Ask (Size) 5.960 (1)
    Prev. Close 6.170
    Today's Range 5.895 - 6.300
    52wk Range 4.970 - 15.74
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
    The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
    Via Talk Markets
    Topics Economy
    Exposures Economy
    Decoding 6 Analyst Evaluations For Recursion Pharmaceuticals
    Via Benzinga

    Performance

    YTD
    -40.02%
    -40.02%
    1 Month
    -7.06%
    -7.06%
    3 Month
    -30.43%
    -30.43%
    6 Month
    -47.10%
    -47.10%
    1 Year
    -29.19%
    -29.19%

    More News

    Read More
    Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Nasdaq Dips Over 2%; US Construction Spending Falls In July
    Via Benzinga
    Recursion Pharmaceuticals Stock Is Sliding Tuesday: What's Going On?
    Via Benzinga
    How Is The Market Feeling About Recursion Pharmaceuticals?
    Via Benzinga
    Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Is Recursion Pharmaceuticals a Warren Buffett Stock?
    Via The Motley Fool
    Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
    Via Talk Markets
    The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.
    Via The Motley Fool
    Is Recursion Pharmaceuticals Stock a Buy?
    Via The Motley Fool
    AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
    Via Talk Markets
    How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    How A.I. Is Shaping the Future of U.S. Healthcare: Regulatory and Market Updates
    From FN Media Group LLC
    Via GlobeNewswire
    Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RXRX, GVP, OBDE, OBDC on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    Prediction: Buying Biotech and Pharma Stocks During This Sell-Off Will Be a Smart Move
    Via The Motley Fool
    Is Recursion Pharmaceuticals a Buy Ahead of Its Merger With Exscientia?
    Via The Motley Fool
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    AI-Powered Drug Discovery Firm Exscientia To Merge With Nvidia-Partner Recursion Pharmaceuticals
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    RXRX Stock Earnings: Recursion Pharmaceuticals Meets EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    RXRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Recursion Pharmaceuticals, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
    From Recursion Pharmaceuticals, Inc.
    Via GlobeNewswire
    Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
    From Recursion Pharmaceuticals
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.